Neratinib: Inching Up on the Cure Rate of HER2 + Breast Cancer?

Neratinib: Inching Up on the Cure Rate of HER2 + Breast Cancer?

Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2 breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib arm compared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2018-08, Vol.24 (15), p.3483-3485
Hauptverfasser: Unni, Nisha, Sudhan, Dhivya R, Arteaga, Carlos L
Format: Artikel
Sprache:eng
Schlagworte:
Breast cancer
Cancer
Crosstalk
ErbB-2 protein
Estrogen receptors
Estrogens
Invasiveness
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2 breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib arm compared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER )/HER2 tumors, suggesting bidirectional cross-talk between the ER and HER pathways. .
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-18-1114